Table 3.
Variables | No. of cases | RECK | ||
---|---|---|---|---|
Negative | Positive | P‐value | ||
Age (years) | ||||
<50 | 60 | 31 | 29 | 0.855 |
≥50 | 59 | 32 | 27 | |
Tumor size | ||||
pT1 | 40 | 16 | 24 | 0.080 |
pT2–T4 | 79 | 46 | 33 | |
Menopausal status | ||||
Premenopausal | 67 | 35 | 32 | 1.000 |
Postmenopausal | 52 | 28 | 24 | |
Histologic grade | ||||
G1 | 13 | 2 | 11 | 0.006 |
G2–G3 | 106 | 61 | 45 | |
Lymph node status | ||||
N0 | 54 | 20 | 34 | 0.002 |
N1–N3 | 65 | 43 | 22 | |
ER status | ||||
Positive | 73 | 38 | 35 | 0.852 |
Negative | 46 | 25 | 21 | |
PR status | ||||
Positive | 67 | 36 | 31 | 0.855 |
Negative | 52 | 27 | 25 | |
HER‐2 status | ||||
Positive (IHC 3+) | 18 | 7 | 11 | 0.573 |
Negative (IHC 1+) | 92 | 35 | 57 | |
Adjuvant systemic therapy | ||||
Yes | 80 | 42 | 38 | 1.000 |
No | 39 | 21 | 18 |
ER, estrogen receptor; NPI, Nottingham prognostic index; PR, progesterone receptor.